ALDERIA INTELLIGENCE
← All signals
PubMed1 Apr 2026·Obesity reviews : an official journal of the International Association for the Study of Obesity● 3/10i

Comparative Efficacy of Different Exercise Interventions on Intrahepatic Lipid Content, Glucose Homeostasis, and Liver Function in Adults With and Without Nonalcoholic Fatty Liver Disease: A Systematic Review With Pairwise and Network Meta-Analyses.

Khalafi M, Fatolahi S, Symonds ME, Rosenkranz SK, Dinizadeh F et al.

High-intensity interval training reduced intrahepatic lipid content most effectively (p-score 0.95), followed by aerobic training (0.77), combined training (0.52), and resistance training (0.10) in adults with and without NAFLD. Network meta-analysis of 38 studies with 1,880 participants comparing exercise interventions. This provides the first head-to-head comparison ranking different exercise modalities for liver fat reduction, filling a critical evidence gap for clinical guidelines and treatment algorithms. Exercise also reduced fasting glucose, insulin, HbA1c, and liver enzymes ALT/AST compared to no exercise.

Strategic signal

This systematic review reinforces exercise as first-line NAFLD treatment, potentially strengthening payer resistance to expensive NAFLD therapies like Madrigal's resmetirom in US and EU markets. Health technology assessment bodies will likely reference this data to justify stepped care approaches requiring lifestyle modification failures before drug coverage. The evidence supports current clinical guidelines positioning exercise before pharmaceutical intervention, creating higher reimbursement barriers for emerging NAFLD treatments.

Liver/NASH

Original Abstract

OBJECTIVES: This study investigated the effects of different exercise interventions on intrahepatic lipid content and markers of glucose homeostasis and liver function in adults with and without nonalcoholic fatty liver disease (NAFLD). METHODS: A comprehensive search was conducted in PubMed, Scopus, Web of Science, and EMBASE using three primary keywords including "exercise training," "liver fat," and "randomization" from inception to August 2025. Eligible studies were those that compared exercise training with either nonexercise groups or other types of exercise training. RESULTS: Thirty-eight studies comprising 1880 participants were included. Exercise training was more effective for reducing intrahepatic lipids [SMD: -0.33, p = 0.001], confirmed through subgroup analyses based on age, health status, body mass index, intervention duration, specific health status, frequency of weekly exercise sessions, biological sex, steatosis classification, and weight change%. Based on the p-score rankings, the intervention that was likely to be the most effective for lowering intrahepatic lipids was high-intensity interval training (p = 0.95), followed by aerobic training (p = 0.77), combined aerobic and resistance training (p = 0.52), and resistance training (p = 0.10). Secondarily, exercise training reduced fasting blood glucose [WMD: -2.27 mg/dL, p = 0.007], fasting insulin [SMD: -0.16, p = 0.02], glycated hemoglobin [SMD: -0.13, p = 0.03], and liver function enzymes including alanine aminotransferase (ALT) [WMD: -3.72 U/L, p = 0.001] and aspartate aminotransferase (AST) [WMD: -3.51 U/L, p = 0.02] significantly more than nonexercise groups. However, there were no significant differences in insulin resistance. CONCLUSIONS: These results provide evidence of the effects of different exercise interventions as part of a healthy lifestyle for reducing intrahepatic lipids and markers of glucose dysmetabolism. PROSPERO Registration: CRD42025639421.

Related signals

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impactPick of the week

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk
ClinicalTrials16 Apr 2026·Phase 3● 7/10i

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase III Trial Evaluating Long-term Efficacy and Safety of Survodutide Weekly Injections in Adult Participants With Noncirrhotic Non-alcoholic Steatohepatitis/Metabolic Dysfunction-associated Steatohepatitis (NASH/MASH) and (F2) - (F3) Stage of Liver Fibrosis

Boehringer Ingelheim is testing survodutide, a weekly injectable, versus placebo in 1,800 adults with MASH and moderate to advanced liver fibrosis (F2-F3). This placebo-controlled trial runs up to 7 years with dual primary endpoints: MASH resolution without fibrosis worsening and composite clinical outcomes including progression to cirrhosis. This positions Boehringer as the first major pharma to advance a dedicated MASH program into Phase 3, targeting a liver indication where Novo's semaglutide and Eli Lilly's tirzepatide have shown promise but lack specific approvals. The 7-year duration reflects the extended timeline needed to demonstrate meaningful liver outcomes in this progressive disease.

Liver/NASHGLP-1Boehringer Ingelheim
ClinicalTrials16 Apr 2026·Phase 3● 7/10i

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

Boehringer Ingelheim is testing survodutide, a once-weekly injectable, in people with compensated NASH/MASH cirrhosis in a phase 3 trial targeting liver-related clinical outcomes. The randomized, placebo-controlled study aims to enroll 1,590 participants over 4.5 years, measuring time to death, liver transplant, hepatic decompensation, or disease progression. This represents Boehringer's entry into the competitive NASH space where Novo Nordisk's semaglutide is already in phase 3 trials for non-cirrhotic NASH. The trial focuses on advanced cirrhotic patients, a population with high unmet need but challenging regulatory pathway.

PubMed14 Apr 2026·Cell metabolism● 6/10i

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Semaglutide improved liver fibrosis, steatosis, and inflammation in mice with MASH through weight-loss-independent mechanisms targeting GLP-1 receptors on liver sinusoidal endothelial cells. Preclinical study using genetically modified mouse models with targeted GLP-1 receptor deletions and transcriptomic profiling. This identifies a novel hepatic mechanism for GLP-1 receptor agonists that could support liver indication development beyond weight loss effects. Study limited to mouse models without human validation.

GLP-1Liver/NASHMechanismsNovo Nordisk

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.